GAMMA Investing LLC Has $962,000 Stake in Scholar Rock Holding Corporation (NASDAQ:SRRK)

GAMMA Investing LLC increased its position in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 3,824.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,928 shares of the company's stock after buying an additional 30,140 shares during the quarter. GAMMA Investing LLC's holdings in Scholar Rock were worth $962,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SRRK. Wellington Management Group LLP boosted its position in shares of Scholar Rock by 763.8% in the 4th quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company's stock valued at $74,581,000 after purchasing an additional 1,525,845 shares during the period. California State Teachers Retirement System boosted its stake in Scholar Rock by 30.1% in the 4th quarter. California State Teachers Retirement System now owns 56,269 shares of the company's stock worth $2,432,000 after purchasing an additional 13,015 shares during the period. Mackenzie Financial Corp acquired a new position in Scholar Rock in the 4th quarter worth approximately $212,000. GF Fund Management CO. LTD. purchased a new position in Scholar Rock during the 4th quarter worth approximately $85,000. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Scholar Rock during the 4th quarter valued at $16,680,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SRRK. Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Wednesday. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research note on Tuesday, June 3rd. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Stock Up 16.6%

Scholar Rock stock traded up $5.17 during mid-day trading on Thursday, hitting $36.32. The company's stock had a trading volume of 5,286,060 shares, compared to its average volume of 1,295,025. The firm's 50 day moving average is $31.52 and its 200 day moving average is $36.08. The company has a market cap of $3.45 billion, a PE ratio of -14.36 and a beta of 0.28. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.25 and a quick ratio of 10.25. Scholar Rock Holding Corporation has a 52-week low of $6.76 and a 52-week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter last year, the business posted ($0.59) earnings per share. On average, analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Insider Activity

In other news, insider Akshay Vaishnaw sold 6,750 shares of Scholar Rock stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $200,610.00. Following the completion of the sale, the insider now directly owns 616,205 shares in the company, valued at $18,313,612.60. The trade was a 1.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey S. Flier sold 6,075 shares of Scholar Rock stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.73, for a total value of $180,609.75. Following the sale, the director now owns 24,070 shares of the company's stock, valued at approximately $715,601.10. This represents a 20.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,500 shares of company stock worth $1,181,671 in the last three months. 13.30% of the stock is owned by insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.